Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.66 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24460754 | 0.86 | GRM2 (0.68) | GRM2SLC9A1TDP1PTK2ALDH1A1 | |
| SCHEMBL28345673 | 0.81 | GRM2 (0.75) | GRM2SLC9A1TDP1PTK2ALDH1A1 | |
| SCHEMBL2734889 | 0.80 | GRM2 (1.00) | GRM2SLC9A1TDP1PTK2ALDH1A1 | |
| SCHEMBL18617433 | 0.80 | ALDH1A1 (0.55) | GRM2SLC9A1TDP1PTK2ALDH1A1 | |
| SCHEMBL24051506 | 0.79 | SLC9A1 (0.68) | GRM2SLC9A1TDP1PTK2KCNMA1 | |
| SCHEMBL30368818 | 0.78 | GAA (0.66) | GRM2SLC9A1TDP1PTK2ALDH1A1 | |
| SCHEMBL9305191 | 0.78 | GAA (0.66) | GRM2SLC9A1TDP1PTK2ALDH1A1 | |
| SCHEMBL20658815 | 0.76 | GRM2 (0.57) | GRM2SLC9A1TDP1PTK2ALDH1A1 | |
| SCHEMBL22000732 | 0.74 | GRM2 (0.75) | GRM2SLC9A1TDP1PTK2LMNA | |
| SCHEMBL7597659 | 0.74 | GRM2 (0.75) | GRM2SLC9A1TDP1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | GRM2 3309/4885SLC9A1 1353/4885TDP1 790/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | GRM2 3309/4885SLC9A1 1353/4885TDP1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.